Characterization of gene mutations and copy number changes in acute myeloid leukemia using a rapid target enrichment protocol
Niccolò Bolli,
Nicla Manes,
Thomas McKerrell,
Jianxiang Chi,
Naomi Park,
Gunes Gundem,
Michael A. Quail,
Vijitha Sathiaseelan,
Bram Herman,
Charles Crawley,
Jenny I. O. Craig,
Natalie Conte,
Carolyn Grove,
Elli Papaemmanuil,
Peter J. Campbell,
Ignacio Varela,
Paul Costeas,
George S. Vassiliou
Affiliations
Niccolò Bolli
Cancer Genome Project, Wellcome Trust Sanger Institute, Cambridge, UK;Department of Haematology, University of Cambridge, UK;Department of Haematology, Addenbrookes Hospital, Cambridge, UK
Nicla Manes
Department of Haematology, Addenbrookes Hospital, Cambridge, UK;Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge, UK
Thomas McKerrell
Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge, UK
Jianxiang Chi
The Center for the Study of Haematological Malignancies, Nicosia, Cyprus
Naomi Park
Sequencing Research and Development, Wellcome Trust Sanger Institute, Cambridge, UK
Gunes Gundem
Cancer Genome Project, Wellcome Trust Sanger Institute, Cambridge, UK
Michael A. Quail
Sequencing Research and Development, Wellcome Trust Sanger Institute, Cambridge, UK
Vijitha Sathiaseelan
Cancer Genome Project, Wellcome Trust Sanger Institute, Cambridge, UK
Bram Herman
Agilent Technologies, Agilent Technologies LDA UK Ltd., Cheadle, UK
Charles Crawley
Department of Haematology, Addenbrookes Hospital, Cambridge, UK
Jenny I. O. Craig
Department of Haematology, Addenbrookes Hospital, Cambridge, UK
Natalie Conte
Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge, UK;EMBL-European Bioinformatics Institute, Cambridge, UK
Carolyn Grove
Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge, UK
Elli Papaemmanuil
Cancer Genome Project, Wellcome Trust Sanger Institute, Cambridge, UK
Peter J. Campbell
Cancer Genome Project, Wellcome Trust Sanger Institute, Cambridge, UK
Ignacio Varela
Instituto de Biomedicina y Biotecnología de Cantabria (CSIC-UC-Sodercan), Departamento de Biología Molecular, Universidad de Cantabria, Santander, Spain
Paul Costeas
The Center for the Study of Haematological Malignancies, Nicosia, Cyprus;Molecular Haematology and Immunogenetics Center, The Karaiskakio Foundation, Nicosia, Cyprus
George S. Vassiliou
Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Cambridge, UK
Prognostic stratification is critical for making therapeutic decisions and maximizing survival of patients with acute myeloid leukemia. Advances in the genomics of acute myeloid leukemia have identified several recurrent gene mutations whose prognostic impact is being deciphered. We used HaloPlex target enrichment and Illumina-based next generation sequencing to study 24 recurrently mutated genes in 42 samples of acute myeloid leukemia with a normal karyotype. Read depth varied between and within genes for the same sample, but was predictable and highly consistent across samples. Consequently, we were able to detect copy number changes, such as an interstitial deletion of BCOR, three MLL partial tandem duplications, and a novel KRAS amplification. With regards to coding mutations, we identified likely oncogenic variants in 41 of 42 samples. NPM1 mutations were the most frequent, followed by FLT3, DNMT3A and TET2. NPM1 and FLT3 indels were reported with good efficiency. We also showed that DNMT3A mutations can persist post-chemotherapy and in 2 cases studied at diagnosis and relapse, we were able to delineate the dynamics of tumor evolution and give insights into order of acquisition of variants. HaloPlex is a quick and reliable target enrichment method that can aid diagnosis and prognostic stratification of acute myeloid leukemia patients.